GRM5 and fragile X syndrome: We used a laboratory-based eye tracking paradigm to demonstrate that mavoglurant, a negative allostatic modulator of mGluR5 activity, significantly improves visual attention to the eyes in adults and adolescents with FXS relative to placebo in the context of a controlled trial.